ArticleCureus2025
Luseogliflozin Suppresses Late-Night Basal Glycemic Variability in Type 2 Diabetes: A Retrospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucose fluctuations have been implicated in the development of diabetic macroangiopathy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are known not only for their glucose-lowering effects but also for their protective effects on the kidneys and heart. Basal glycemic variability (GV) during late-night periods, when external factors such as meals and physical activity are minimized, may represent a clinically important marker of intrinsic glucose regulation. However, little is known about the impact of SGLT2 inhibitors on basal GV. This study investigated the acute (within 24 hours) effect of the first administration of luseogliflozin, an SGLT2 inhibitor, on nocturnal basal GV in patients with type 2 diabetes mellitus. PATIENTS AND
methodsTen patients with type 2 diabetes who met the criteria were retrospectively selected. Luseogliflozin (2.5 mg/day) was initiated after baseline assessment. Continuous glucose monitoring (CGM; FreeStyle Libre Pro, Abbott Diabetes Care Inc., Alameda, California) was performed, and the coefficient of variation (CV) of glucose was calculated as an index of glycemic variability (GV). Nocturnal basal GV was evaluated between 11:00 P.M. and 3:00 A.M. on the night before and the night after the first administration. This study was retrospective because CGM data before and after luseogliflozin initiation were obtained from existing hospital records, without prior intent to evaluate this specific effect.
resultsCGM revealed heterogeneous nocturnal glucose patterns with small but clinically relevant fluctuations. Luseogliflozin significantly reduced nocturnal glucose CV from 11.9% ± 3.8% at baseline to 7.2% ± 4.1% after treatment (p = 0.0048). These findings indicate that even after the first dose, luseogliflozin may acutely stabilize basal glucose fluctuations during late-night periods.
conclusionThis is the first study to demonstrate that an SGLT2 inhibitor can suppress nocturnal basal GV immediately after initiation. Given that GV has been associated with sympathetic activation and vascular injury, these results suggest that reducing basal GV with SGLT2 inhibitors may contribute to vascular protection. Further studies with larger sample sizes and longer follow-up are warranted to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.